Pasithea completes enrollment and initial dosing of first Cohort from its phase 1/1b trial of PAS-004 in adult NF1 patients

Pasithea Therapeutics Corp. (Pasithea), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway

To access the full article, please log in or subscribe.